|
**Overview**: Hemoglobin Electrophoresis Panel**Introduction**: The Hemoglobin Electrophoresis Panel is a diagnostic tool designed to screen for hemoglobinopathies using whole blood samples. In India, hemoglobinopathies (thalassemia, sickle cell disease, HbE, HbD) affect millions (~40 million carriers, ~100,000 thalassemia major births/year), with electrophoresis identifying Hb variants for diagnosis and carrier screening. High morbidity from under-testing in rural/low-SES populations (tribal areas with sickle cell, northern states with beta-thalassemia), limited labs, delayed transfusion/chelation or prenatal counseling leading to severe anemia or mortality. Per hematology practices aligned with ICMR and National Thalassemia Control Programme guidelines, the test employs electrophoresis for HbA, HbA2, HbF, HbS, HbC, HbD, HbE, and other variants over 1-2 days with high accuracy, valuable for anemia workup and premarital screening. This diagnostic falls under anemia screening and targets patients with microcytic anemia, family history, or ethnic risk, addressing accurate detection to guide transfusion, chelation, or counseling. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise variant identification and reducing hemoglobinopathy burden. Its whole blood-based approach ensures reliable separation.**Other Names**: Hb Electro Pnl.**FDA Status**: FDA approved, CLIA certified for hematology, compliant with 2025 standards.**Historical Milestone**: Hb electrophoresis standard; in India, key in thalassemia programs.**Purpose**: The test assesses 10 parameters including HbA to guide hemoglobinopathy screening, detect variants, inform management.**Test Parameters**: 1. HbA, 2. HbA2, 3. HbF, 4. HbS, 5. HbC, 6. HbD, 7. HbE, 8â€"10. Other Variants.**Pretest Condition**: No fasting required; patients should report anemia or family history.**Specimen**: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve cell integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for electrophoresis).**Medical History**: Patients should provide details on anemia type, ethnicity, family history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undiagnosed hemoglobinopathy including severe anemia, benefits of screening, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using electrophoresis by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or recent transfusion can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal Hb variants indicate hemoglobinopathy, necessitating specialist input. Normal may require follow-up.**Specialist Consultation**: Hematologists should be consulted for management.**Additional Supporting Tests**: HPLC, DNA analysis for confirmation.**Test Limitations**: May miss rare variants; comprehensive approach required.**References**: Indian Journal of Hematology 2024, Hemoglobinopathy Studies India 2023. |
